Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Joanne L. Blum(Texas Oncology), Dale E. Shuster(Daiichi Sankyo (United States)), Elizabeth Tan-Chiu(SUNY Upstate Medical University), Joyce O’Shaughnessy(Baylor University Medical Center), Kumari Chandrawansa(SUNY Upstate Medical University), John W. Smith(SUNY Upstate Medical University), Carol J. Fabian(Washington Hospital), Fang Fang(Jinshan Hospital of Fudan University), David A. Smith(SUNY Upstate Medical University), Simon Ashworth(SUNY Upstate Medical University), Jonathan Wright(SUNY Upstate Medical University), Patricia E. Cole(Takeda (United States)), Nicole Meneses(Eisai (United States)), N. D'Acosta(SUNY Upstate Medical University), Ellen Chuang(SUNY Upstate Medical University), Brian Pruitt(SUNY Upstate Medical University), Ragene Rivera(SUNY Upstate Medical University), Antoinette R. Tan(Wake Forest University)
Cited by 245
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
|Nature|2015|1.8k
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
Connecting copper and cancer: from transition metal signalling to metalloplasia
|Nature reviews. Cancer|2021|1.3k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k